Product Details
In the field of gene function research and drug development, the primary advantage of siRNAs over small molecule inhibitors, chemotherapeutics or antibodies is their high specificity and high throughput screening. siRNAs can target different target genes by optimizing the location and modification of RNAi targeting sequences to achieve gene expression silencing and further rapid development of new drugs, and their screening and development timelines are usually better than those of chemotherapeutics and antibodies. The screening and development time is usually better than that of chemical drugs and antibody drugs.
siRNA service | Regular siRNA | Modified siRNA | UHP siRNA | Animal-grade in vivo-siRNA |
Application | Suitable for preliminary screening of RNAi in various cells | Increase siRNA stability and effectively inhibit target gene expression | Ensure ultra-high performance of silencing specificity, efficiency and stability of each siRNA sequence | Can be injected directly into the animal for systemic or partial drug delivery |
Advantages
1. Professional technical design, special optimized sequences and modifications to ensure that siRNA can achieve more than 70% silencing effect;
2. Designing synthetic siRNAs for more regions of the same mRNA to improve the success rate of silencing target genes;
3. After-sales commitment: we promise that the experimental data you provide (transfection efficiency picture or positive control results [can be either, need to achieve 80% transfection efficiency or positive interference effect of 70%] with qPCR primers and the original results), through qPCR identification, the set of 3 pairs of siRNA to determine that no one in any one cell does not reach 70% of the silencing effect, commitment to redesign and free synthesis of another 3 pairs of siRNA for the target gene once and give the corresponding control.
Component
S/N | Services | Specification |
PRsi001 | siRNA regular single-target synthesis | 2.5nmol |
PRsiu002 | UHP- siRNA chemical modified single-target synthesis | 2.5nmol |
PRsit003 | siRNA regular 1/3 package synthesis | 5nmol*3 |
PRsit003 | siRNA regular 2/5 package synthesis | 5nmol*5 |
PRsit004 | siRNA regular 1/3 ready-to-use package synthesis | 5nmol*3 |
PRsit004 | siRNA regular 2/5 Ready-to-Use Package Synthesis | 5nmol*5 |
Prsiut005 | UHP-siRNA chemical modified 1/3 package synthesis | 5nmol*3 |
Prsiut005 | UHP-siRNA chemical modified 2/5 package synthesis | 5nmol*5 |
Prsiut006 | UHP-siRNA chemical modified 1/3 ready-to-use package synthesis | 5nmol*3 |
Prsiut006 | UHP-siRNA chemical modified 2/5 ready-to-use package synthesis | 5nmol*5 |